Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: A pediatric tertiary care center experience

European Journal of Pediatrics

Volumn 169, Issue 11, 2010, Pages 1311-1315

  Crisinel, Pierre Alex ^a   Chevalier, Isabelle ^a   Rallu, Fabien ^a   Tapiero, Bruce ^a   Lamarre, Valérie ^a   Thibault, Roseline ^b   Ovetchkine, Philippe ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Invasive pneumococcal disease; Pneumococcal vaccine; Reduced dose

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ARTICLE; CHILD; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFANT; MAJOR CLINICAL STUDY; PEDIATRIC HOSPITAL; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; TERTIARY HEALTH CARE;

EID: 77957652858     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-010-1214-7     Document Type: Article

References (19)

1. -2008. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. Morb Mortal Wkly Rep 57:144-148
2. Bettinger JA, Scheifele DW, Kellner JD et al. (2009) The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine
3. S Black EK France D Isaacman, et al. 2007 Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine Pediatr Infect Dis J 26 771 777 10.1097/INF.0b013e318124a494 17721369
4. EH Choi SH Kim BW Eun, et al. 2008 Streptococcus pneumoniae serotype 19A in children, South Korea Emerg Infect Dis 14 275 281 1:CAS:528: DC%2BD1cXivVOrsrc%3D 10.3201/eid1402.070807 18258121
5. R Dagan N Givon-Lavi E Leibovitz, et al. 2009 Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population J Infect Dis 199 776 785 1:CAS:528:DC%2BD1MXktVygt70%3D 10.1086/597044 19434927
6. P De Wals N Boulianne E Sévin, et al. 2009 Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs Can J Public Health 100 413 416 20209732
7. P De Wals E Robin E Fortin, et al. 2008 Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada Pediatr Infect Dis J 27 963 968 10.1097/INF.0b013e31817cf76f 18845982
8. D Goldblatt J Southern L Ashton, et al. 2006 Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers Pediatr Infect Dis J 25 312 319 10.1097/01.inf.0000207483.60267.e7 16567982
9. ZB Harboe TL Benfield P Valentiner-Branth, et al. 2010 Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades Clin Infect Dis 50 329 337 10.1086/649872 20047478
10. LA Hicks LH Harrison B Flannery, et al. 2007 Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004 J Infect Dis 196 1346 1354 10.1086/521626 17922399
11. HE Hsu KA Shutt MR Moore, et al. 2009 Effect of pneumococcal conjugate vaccine on pneumococcal meningitis N Engl J Med 360 244 256 1:CAS:528: DC%2BD1MXnsFCrsw%3D%3D 10.1056/NEJMoa0800836 19144940
12. JD Kellner OG Vanderkooi J MacDonald, et al. 2009 Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study Clin Infect Dis 49 205 212 10.1086/599827 19508165
13. Jetté L, Bourgault AM, Raynal L, De Wals P. 2008. Impact of 7-valent pneumococcal conjugate (PCV7) on serotype distribution and susceptibility profiles of invasive S. pneumoniae (ISp) isolates in Quebec, 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC
14. MR Moore RE Gertz RL Woodbury, et al. 2008 Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005 J Infect Dis 197 1016 1027 10.1086/528996 18419539
15. MR Moore CG Whitney 2008 Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin Infect Dis 46 183 185 10.1086/524661 18171248
16. SI Pelton H Huot JA Finkelstein, et al. 2007 Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine Pediatr Infect Dis J 26 468 472 10.1097/INF.0b013e31803df9ca 17529860
17. S Ruckinger M van der Linden RR Reinert, et al. 2009 Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany Vaccine 27 4136 4141 10.1016/j.vaccine.2009.04.057 19406190
18. RJ Singleton TW Hennessy LR Bulkow, et al. 2007 Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage JAMA 297 1784 1792 1:CAS:528:DC%2BD2sXkslCku7o%3D 10.1001/jama.297.16.1784 17456820
19. CG Whitney T Pilishvili MM Farley, et al. 2006 Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study Lancet 368 1495 1502 1:CAS:528: DC%2BD28XhtFent7jM 10.1016/S0140-6736(06)69637-2 17071283